Targeted Synthetic DMARDs vs. Biologics in the Management of RA

PRESENTER: Jonathan Kay, MD

Professor, University of Massachusetts Medical School
Director of Clinical Research, Rheumatology
UMass Memorial Medical Center
Worcester, MA

Credits: 0.5

Release Date: April 14, 2020

Expiration Date: April 14, 2021

*This program has expired. CME credit is no longer available.

Target Audience:This activity has been designed to meet the educational needs of rheumatologists, physicians, physician assistants, and nurse practitioners involved in the care of patients with psoriatic disease.

Learning Objectives: After the completion of this activity, participants should be able to:

  • Review data on the currently approved targeted synthetic DMARDs (tsDMARDs) for RA
  • Understand the potential risks of approved tsDMARDs
  • Discuss how to incorporate approved tsDMARDs for RA in clinical practice
  • Present the new tsDMARDs currently being studied
  • Note: This presentation will include discussion of non-FDA approved drugs in the treatment of RA.

    STATEMENT OF SUPPORT: This activity is supported by educational grants from AbbVie, Amgen, Crescendo Bioscience, Inc., Janssen Biotech, Inc., Sandoz Inc., a Novartis Division, Sanofi

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

    Purdue University College of Pharmacy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

    This program has been approved for 0.5 contact hours.

    All faculty and staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

    All additional planning committee members, reviewers and Purdue University College of Pharmacy and Focus Medical Communications staff have no relationships to disclose.

    Principal Investigator for a Drug Study: Flexion Therapeutics Inc.; Gilead Sciences Inc.; Pfizer Inc.
    Consultant: Alvotech Suisse AG; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim GmbH; Celltrion Healthcare Co. Ltd.; Merck Sharp & Dohme Corp.; Mylan Inc.; Novartis AG; Samsung Bioepis; Sandoz Inc.; UCB, Inc.
    Editorial Board Involvement: Member, Editorial Board, Best Practice and Research Clinical Rheumatology; Advisory Editor, Arthritis & Rheumatology; Member, Advisory Committee, RMD Open